Name: 글로벌 시장 동향
SKU: MD617
Availability: InStock

보고서 요약(국문)

보고서 개요
세계 무균 주사제 시장은 2023년 5,773억 2천만 달러에 달했으며, 2024년부터 2031년까지 연평균 7.8%의 성장률로 2031년에는 1조 81억 1천만 달러에 이를 것으로 예상됩니다.
세계 무균 주사제 시장은 혈류 또는 인체 조직에 직접 투여되는 주사형 의약품 제형을 포함하는 분야입니다. 이러한 제형은 경구용 정제나 스프레이와 같은 다른 형태의 약물에 비해 흡수 속도가 빠르고 효과가 뛰어나 다양한 질환, 특히 만성 질환 치료에 매우 중요합니다.
무균 주사제는 살아있는 미생물이 완전히 제거된 제형으로, 일반적으로 주사를 통해 투여됩니다. 이 범주에는 백신, 단클론 항체 및 기타 생물학적 제제를 포함한 다양한 제품이 포함됩니다.
이러한 약물은 정맥 주사(IV), 근육 주사(IM) 또는 피하 주사(SC)와 같은 다양한 경로를 통해 투여될 수 있습니다. 이러한 투여 방법은 신속한 치료 효과를 가능하게 하고 활성 의약 성분을 혈류 또는 특정 조직에 직접 전달하여 다른 투여 경로에서 발생할 수 있는 잠재적 장벽이나 분해를 우회할 수 있습니다.
시장 동향: 성장 동력
만성 질환의 증가와 기술 발전
전 세계 무균 주사제 시장의 수요는 여러 요인에 의해 주도됩니다. 주요 요인 중 하나는 만성 질환의 증가와 기술 발전입니다. 암, 당뇨병, 심장병과 같은 만성 질환의 전 세계적인 발생률 증가는 무균 주사제 시장 성장을 촉진하는 중요한 동력입니다. 이러한 만성 질환 치료에 여러 주사제가 사용됨에 따라 무균 주사제 제형에 대한 수요가 증가하고 있습니다.
세계보건기구(WHO)의 2023년 9월 자료에 따르면 만성 질환은 전 세계 사망 원인의 약 71%를 차지하며, 이는 심각한 공중 보건 문제임을 보여줍니다. 무균 주사제는 다양한 만성 질환 관리를 위한 중요한 치료법으로 부상하고 있습니다. 더욱이, 사전 충전형 주사기와 자동 주입기의 지속적인 발전으로 주사 약물 치료가 점점 더 편리하고 사용자 친화적으로 변하고 있습니다. 이러한 혁신은 환자와 의료진 모두 주사 치료법을 더욱 널리 채택하도록 촉진하고 있습니다.
또한, 업계 주요 기업들의 시장 확장 및 핵심 개발 전략과 같은 투자가 시장 성장을 견인하고 있습니다. 예를 들어, 브리지웨스트 그룹(Bridgewest Group)은 2023년 4월 무균 주사제에 특화된 새로운 위탁 개발 및 제조 조직(CDMO)을 설립했습니다. 이는 브리지웨스트가 최근 호주 퍼스에 있는 화이자(Pfizer)의 무균 주사제 제조 공장을 인수한 데 따른 것입니다.
마찬가지로, 우시 STA(WuXi STA)는 2023년 7월 중국 우시시에 위치한 의약품 생산 시설에 최첨단 무균 주사제 생산 라인을 구축했습니다. 이 라인은 연간 1,200만 개의 생산 능력을 갖추고 있어 우시 STA가 증가하는 무균 주사제 수요를 충족할 수 있도록 합니다. 제조 공정에는 완전 밀폐형 격리 시스템과 자동 충전 기계가 사용됩니다. 이는 인적 개입과 노출을 최소화하여 제품 품질과 작업자 안전을 향상시킵니다.
또한, 2023년 8월, 화이자는 노스캐롤라이나에 있는 제조 공장에 피해를 입힌 토네이도로 인해 수요가 급증하자 특정 무균 주사제에 대한 긴급 주문 절차를 시행했습니다. 이 긴급 조치를 통해 화이자는 특정 무균 주사제를 고객에게 직접 배송하여 공급 차질 기간 동안 이러한 필수 의약품에 대한 지속적인 접근성을 보장할 수 있습니다.
제약 요인
높은 개발 비용, 엄격한 규제 요건, 복잡한 제조 공정, 특허 만료 및 상환 문제와 같은 요인들이 시장 성장을 저해할 것으로 예상됩니다.
시장 세분화 분석
전 세계 무균 주사제 시장은 분자 유형, 약물 종류, 적용 분야, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
단클론 항체(mAb) 부문은 전 세계 무균 주사제 시장 점유율의 약 40.6%를 차지했습니다.
단클론 항체(mAb) 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 암, 자가면역 질환, 심혈관 질환과 같은 만성 질환 치료에 단일클론항체(mAb) 요법의 사용이 증가함에 따라 전 세계 무균 주사제 시장에서 mAb 주사제에 대한 수요가 증가하고 있습니다.
또한, 업계 주요 기업들의 혁신적인 제품 출시 및 승인이 시장 성장을 견인하고 있습니다. 예를 들어, 2024년 5월 로슈 파마 인도는 신생혈관성 또는 "습성" 연령 관련 황반변성(nAMD) 및 당뇨병성 황반부종(DME) 치료제인 바비스모(파리시맙)를 출시하며 안과 시장에 공식 진출했습니다. nAMD와 DME는 전 세계적으로 수백만 명에게 영향을 미치는 주요 시력 손실 원인입니다.
마찬가지로, 2023년 12월 JSR 라이프 사이언스의 자회사인 KBI 바이오파마는 SURE 기술 플랫폼을 기반으로 개발된 새로운 제품인 SUREmAb를 출시했습니다. 이 혁신적인 플랫폼은 단클론 항체(mAb)의 개발 및 제조 공정을 최적화하여 더욱 효율적이고 안전하며 비용 효율적인 항체를 생산하도록 설계되었습니다.
또한, 2023년 6월 UCB는 미국 식품의약국(FDA)이 항아세틸콜린 수용체(AChR) 항체 또는 항근육 특이적 티로신 키나제(MuSK) 항체 양성인 성인 환자의 전신성 중증근무력증(gMG) 치료제로 RYSTIGGO(로자놀릭시주맙-놀리)를 승인했다고 발표했습니다. 이 승인은 수의근의 약화와 빠른 피로를 특징으로 하는 만성 자가면역 신경근육 질환인 gMG에 대한 치료 옵션에 있어 중요한 진전을 의미합니다.

시장 지역 분석
북미는 전 세계 무균 주사제 시장 점유율의 약 43.6%를 차지했습니다.
북미 지역은 만성 질환 증가, 고령화, 그리고 잘 발달된 의료 인프라로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상되며, 이러한 요인들이 해당 지역 시장 성장을 견인하고 있습니다.
또한, 이 지역에서는 다수의 주요 기업들이 활동하고 있으며, 재정 투자, 정부 정책 및 지원, 그리고 신제품 출시가 시장 성장을 촉진하고 있습니다. 예를 들어, 2024년 7월 뉴저지에서 암닐 파마슈티컬스(Amneal Pharmaceuticals)는 기존 포사프레피탄트 제품보다 여러 가지 장점을 제공하는 혁신적인 즉시 사용 무균 주사제인 포신베즈(FOCINVEZ, 포사프레피탄트)를 출시했습니다. 포신베즈는 혁신적인 제형 개발에 주력하는 전문 연구 개발 기업인 SPES 파마슈티컬스(SPES Pharmaceuticals)에서 개발했으며, 글로벌 무균 주사제 CDMO인 스테리사이언스(Steriscience)에서 제조합니다. 이 혁신적인 포사프레피탄트 제품의 출시는 독특한 제형과 사용 편의성을 통해 투여 효율성과 안전성을 향상시키도록 설계되어 화학요법을 받는 환자들에게 중요한 새로운 치료 옵션을 제공합니다.
마찬가지로, 주사제, 마취제 및 조제약 분야의 글로벌 리더인 Baxter International Inc.는 2024년 4월 미국에서 5가지 새로운 주사제 제품 출시를 발표하며 제약 포트폴리오를 확장했습니다. 이러한 출시는 항감염제 및 항저혈압제를 포함한 주요 치료 분야에서 충족되지 않은 환자 요구를 해결하는 차별화된 제품 개발에 대한 Baxter의 노력을 보여줍니다.
또한, 캐나다 최대 제약 회사인 Pharmascience는 2024년 2월 퀘벡주 캔디악에 위치한 무균 주사제 제조 시설을 1억 2천만 달러를 투자하여 대폭 확장한다고 발표했습니다. 이번 확장은 무균 주사제 생산 능력을 강화하고 제약 시장에서의 입지를 공고히 하려는 Pharmascience에게 중요한 이정표입니다.

시장 세분화
분자 유형별
소분자
대분자
약물 종류별
단클론항체(mAb)
사이토카인
인슐린
펩타이드 호르몬
백신
면역글로불린
혈액인자
펩타이드 항생제
기타
적용 분야별
종양학
심혈관 질환
신경학
자가면역 질환
감염성 질환
당뇨병
기타
투여 경로별
피하(SC)
정맥(IV)
근육(IM)
기타
유통 채널별
병원 약국
온라인 약국
소매 약국
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽
남미 미주
브라질
아르헨티나
남미 기타 지역
아시아 태평양
중국
인도
일본
한국
아시아 태평양 기타 지역
중동 및 아프리카
시장 경쟁 구도
멸균 주사제 시장의 주요 글로벌 업체로는 Pfizer Inc., Merck & Co., Inc., Novartis AG, Sanofi, GSK plc, AbbVie Inc., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Amgen Inc., Teva Pharmaceuticals USA, Inc. 등이 있습니다.
주요 동향
2024년 6월, Sharp Services는 펜실베이니아주 매컨지에 있는 시설을 대폭 확장하여 멸균 주사제 2차 포장재 생산 능력을 강화한다고 발표했습니다. 이러한 전략적 움직임은 제약 및 바이오 기술 분야에서 증가하는 멸균 주사제 수요를 충족하기 위한 것입니다.

2024년 6월, 보라 제약(Bora Pharmaceuticals Co., Ltd.)은 메릴랜드주 볼티모어-캠든에 위치한 에머전트 바이오솔루션(Emergent BioSolutions)의 무균 제조 시설을 인수하기로 합의함으로써 사업 확장 전략에 있어 중요한 발걸음을 내디뎠습니다. 이번 인수는 보라의 첫 번째 무균 제조 시설 확보이며, 무균 주사제 제조 역량을 강화하기 위한 전략적 움직임입니다.
2023년 3월, 히크마 제약(Hikma Pharmaceuticals PLC)은 캐나다에서 4가지 신규 무균 주사제를 출시하며 해당 지역에서의 제품 포트폴리오를 크게 확장했습니다. 이는 환자와 의료진 모두에게 중요한 새로운 치료 옵션을 제공하고 캐나다 시장에서 히크마의 입지를 강화하는 데 중요한 의미를 갖습니다.
보고서 구매 이유:
분자 유형, 약물 종류, 적용 분야, 투여 경로, 유통 채널 및 지역별 글로벌 무균 주사제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위함입니다.

모든 세그먼트를 포함한 무균 주사제 시장의 다양한 데이터 포인트가 담긴 엑셀 데이터 시트입니다.

PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑이 엑셀 파일로 제공됩니다.
글로벌 무균 주사제 시장 보고서는 약 78개의 표, 82개의 그림, 그리고 184페이지 분량입니다.
주요 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자 은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Sterile Injectable Market reached US$ 577.32 billion in 2023 and is expected to reach US$ 1008.11 billion by 2031 growing with a CAGR of 7.8% during the forecast period 2024-2031.
The global sterile injectable market refers to the sector involving injectable pharmaceutical formulations administered directly into the bloodstream or human tissues. These formulations are critical for treating various medical conditions, especially chronic diseases, due to their rapid absorption and effectiveness compared to other forms of medication, such as oral tablets or sprays.
Sterile injectable medications are formulations that must be completely devoid of living microorganisms and are commonly administered through injections. This category encompasses various products, including vaccines, monoclonal antibodies, and other biological drugs.
These medications can be delivered via various routes, such as intravenous (IV) infusions, intramuscular (IM) shots, or subcutaneous (SC) injections. These administration methods enable rapid therapeutic action and targeted delivery of the active pharmaceutical ingredients directly into the bloodstream or specific tissues, bypassing potential barriers or degradation that may occur with other routes of administration.
Market Dynamics: Drivers
Rising prevalence of chronic diseases and technological advancements
The demand for the global sterile injectable market is driven by multiple factors. One of the primary factors is the rising prevalence of chronic diseases and technological advancements. The growing incidence of chronic illnesses worldwide, such as cancer, diabetes, and heart disease, is a significant driver propelling the sterile injectables market growth. Several injectable medications are utilized in the treatment of these chronic conditions, thereby stimulating the demand for sterile injectable formulations.
According to the World Health Organization (WHO) data in September 2023, indicating that chronic diseases are responsible for approximately 71% of global deaths highlights a significant public health challenge. Sterile injectable drugs have emerged as a crucial treatment modality for managing various chronic diseases. Moreover, ongoing advancements in prefilled syringes and autoinjectors are making injectable drug therapies increasingly convenient and user-friendly. These innovations are fueling greater adoption of injectable treatments by patients and healthcare providers.
In addition, major players in the industry investments such as the expansion of the market, and key development strategies are driving the market growth. For instance, in April 2023, Bridgewest Group launched a new Contract Development and Manufacturing Organization (CDMO) focused on sterile injectable drug products. This follows Bridgewest's recent acquisition of Pfizer's sterile injectable manufacturing plant in Perth, Australia.
Similarly, in July 2023, WuXi STA launched a state-of-the-art sterile injectable manufacturing line at its drug product facility in Wuxi City, China. The line has an annual capacity of 12 million units, allowing WuXi STA to meet the growing demand for sterile injectable drugs. The manufacturing process utilizes fully enclosed isolation systems and automated filling machines. This minimizes human intervention and exposure, enhancing product quality and worker safety.
Also, in August 2023, Pfizer implemented an emergency ordering process for certain sterile injectable products due to a significant increase in demand following a tornado that impacted its manufacturing plant in North Carolina. This emergency measure allows Pfizer to ship specific sterile injectables directly to customers, ensuring continued access to these critical medications during the disruption.
Restraints
Factors such as high development costs, stringent regulatory requirements, complex manufacturing processes, patent expiration & reimbursement challenges, are expected to hamper the market.
Market Segment Analysis
The global sterile injectable market is segmented based on molecule type, drug class, application, route of administration, distribution channels, and region.
The monoclonal antibodies (mAbs) segment accounted for approximately 40.6% of the global sterile injectable market share
The monoclonal antibodies (mAbs) segment is expected to hold the largest market share over the forecast period. The increasing use of monoclonal antibody (mAb) therapies to treat chronic conditions such as cancer, autoimmune disorders, and cardiovascular diseases is a significant factor driving demand for mAb injectables in the global sterile injectables market.
Moreover, key players in the industry's innovative product launches and approvals are helping to drive this segment growth in the market. For instance, in May 2024, Roche Pharma India officially entered the ophthalmology market with the launch of Vabysmo (faricimab), a groundbreaking treatment for neovascular or "wet" age-related macular degeneration (nAMD) and diabetic macular edema (DME). Both nAMD and DME are significant contributors to vision loss globally, affecting millions of individuals.
Similarly, in December 2023, KBI Biopharma, Inc., a subsidiary of JSR Life Sciences, launched SUREmAb, a new offering built on its SUREtechnology Platform. This innovative platform is designed to optimize the development and manufacturing processes of monoclonal antibodies (mAbs), making them more efficient, safe, and cost-effective.
Also, in June 2023, UCB announced that the U.S. Food and Drug Administration (FDA) has approved RYSTIGGO (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are positive for either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This approval marks a significant advancement in the treatment options available for gMG, a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles.
Market Geographical Analysis
North America accounted for approximately 43.6% of the global sterile injectable market share
North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of chronic diseases, aging population, and well-advanced healthcare infrastructure, which are driving this market growth in this region.
Moreover, in this region, a major number of key players' presence, financial investments, government initiatives & support, and product launches are helping to propel this market growth. For instance, in July 2024, in New Jersey, Amneal Pharmaceuticals launched FOCINVEZ (fosaprepitant), a novel ready-to-use sterile injectable that offers several advantages over existing fosaprepitant products. FOCINVEZ was developed by SPES Pharmaceuticals, a specialized R&D firm focused on innovative formulations, and is manufactured by Steriscience, a global sterile injectables CDMO. The launch of this innovative fosaprepitant product represents an important new treatment option for patients undergoing chemotherapy, with its unique formulation and ease-of-use features designed to improve efficiency and safety in administration.
Similarly, in April 2024, Baxter International Inc., a global leader in injectables, anesthesia, and drug compounding, announced the launch of five new injectable products in the U.S., expanding its Pharmaceuticals portfolio. These launches demonstrate Baxter's focus on developing differentiated products that address unmet patient needs in critical therapeutic areas, including anti-infective and anti-hypotensive medications.
Also, in February 2024, Pharmascience, the largest Canadian-owned pharmaceutical company, announced a significant expansion of its sterile injectable manufacturing facility located in Candiac, Quebec, with a substantial investment of $120 million. This expansion is a pivotal milestone for the company as it aims to enhance its capabilities in producing sterile injectables and strengthen its position in the pharmaceutical market.
Market Segmentation
By Molecule Type
Small Molecule
Large Molecule
By Drug Class
Monoclonal Antibodies (mAbs)
Cytokines
Insulin
Peptide Hormones
Vaccines
Immunoglobulins
Blood Factors
Peptide Antibiotics
Others
By Application
Oncology
Cardiovascular Diseases
Neurology
Autoimmune Diseases
Infectious Diseases
Diabetes
Others
By Route of Administration
Subcutaneous (SC)
Intravenous (IV)
Intramuscular (IM)
Others
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the sterile injectable market include Pfizer Inc., Merck & Co., Inc., Novartis AG, Sanofi, GSK plc, AbbVie Inc., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Amgen Inc., and Teva Pharmaceuticals USA, Inc. among others.
Key Developments
In June 2024, Sharp Services announced a significant expansion of its facility in Macungie, Pennsylvania, aimed at enhancing its production capacity for sterile injectable secondary packaging. This strategic move is designed to meet the increasing demand for sterile injectables in the pharmaceutical and biotech sectors.
In June 2024, Bora Pharmaceuticals Co., Ltd. announced a significant step in its commercial expansion strategy by agreeing to acquire Emergent BioSolutions' sterile manufacturing facility located in Baltimore-Camden, Maryland. This acquisition marks Bora's first sterile manufacturing facility and is a strategic move to enhance its capabilities in sterile injectable drug product manufacturing.
In March 2023, Hikma Pharmaceuticals PLC announced the launch of four new sterile injectable medicines in Canada, marking a significant expansion of its product offerings in the region. This development is crucial for both patients and healthcare providers, as it introduces important new treatment options and reinforces Hikma's growing presence in the Canadian market.
Why Purchase the Report?
To visualize the global sterile injectable market segmentation based on molecule type, drug class, application, route of administration, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the sterile injectable market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in excel consisting of key products of all the major players.
The global sterile injectable market report would provide approximately 78 tables, 82 figures, and 184 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Molecule Type
3.2. Snippet by Drug Class
3.3. Snippet by Application
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channels
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Chronic Diseases and Technological Advancements
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High Development Costs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Molecule Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
6.1.2. Market Attractiveness Index, By Molecule Type
6.2. Small Molecule*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Large Molecule
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Monoclonal Antibodies (mAbs) *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cytokines
7.4. Insulin
7.5. Peptide Hormones
7.6. Vaccines
7.7. Immunoglobulins
7.8. Blood Factors
7.9. Peptide Antibiotics
7.10. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Oncology*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular Diseases
8.4. Neurology
8.5. Autoimmune Diseases
8.6. Infectious Diseases
8.7. Diabetes
8.8. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Subcutaneous (SC) *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous (IV)
9.4. Intramuscular (IM)
9.5. Others
10. By Distribution Channels
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.1.2. Market Attractiveness Index, By Distribution Channels
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies *
10.4. Online Pharmacies *
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. U.K.
11.3.8.3. France
11.3.8.4. Spain
11.3.8.5. Italy
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Merck & Co., Inc.
13.3. Novartis AG
13.4. Sanofi
13.5. GSK plc
13.6. AbbVie Inc
13.7. F. Hoffmann-La Roche Ltd
13.8. Gilead Sciences, Inc.
13.9. Amgen Inc.
13.10. Teva Pharmaceuticals USA, Inc. (*LIST NOT EXHAUSTIVE)
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, Merck & Co., Inc., Novartis AG, Sanofi, GSK plc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Amgen Inc.

표 목록 (Tables)

List of Tables Table 1 Global Sterile Injectables Market Value, By Molecule, 2025, 2029 & 2033 (US$ Million)

Table 2 Global Sterile Injectables Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)

Table 3 Global Sterile Injectables Market Value, By Therapeutic Area, 2025, 2029 & 2033 (US$ Million)

Table 4 Global Sterile Injectables Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)

Table 5 Global Sterile Injectables Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Million)

Table 6 Global Sterile Injectables Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 7 Global Sterile Injectables Market Value, By Molecule, 2025, 2029 & 2033 (US$ Million)

Table 8 Global Sterile Injectables Market Value, By Molecule, 2022-2033 (US$ Million)

Table 9 Global Sterile Injectables Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)

Table 10 Global Sterile Injectables Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 11 Global Sterile Injectables Market Value, By Therapeutic Area, 2025, 2029 & 2033 (US$ Million)

Table 12 Global Sterile Injectables Market Value, By Therapeutic Area, 2022-2033 (US$ Million)

Table 13 Global Sterile Injectables Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)

Table 14 Global Sterile Injectables Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 15 Global Sterile Injectables Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Million)

Table 16 Global Sterile Injectables Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 17 Global Sterile Injectables Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 18 Global Sterile Injectables Market Value, By Region, 2022-2033 (US$ Million)

Table 19 North America Sterile Injectables Market Value, By Molecule, 2022-2033 (US$ Million)

Table 20 North America Sterile Injectables Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 21 North America Sterile Injectables Market Value, By Therapeutic Area, 2022-2033 (US$ Million)

Table 22 North America Sterile Injectables Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 23 North America Sterile Injectables Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 24 North America Sterile Injectables Market Value, By Country, 2022-2033 (US$ Million)

Table 25 Europe Sterile Injectables Market Value, By Molecule, 2022-2033 (US$ Million)

Table 26 Europe Sterile Injectables Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 27 Europe Sterile Injectables Market Value, By Therapeutic Area, 2022-2033 (US$ Million)

Table 28 Europe Sterile Injectables Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 29 Europe Sterile Injectables Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 30 Europe Sterile Injectables Market Value, By Country, 2022-2033 (US$ Million)

Table 31 Asia-Pacific Sterile Injectables Market Value, By Molecule, 2022-2033 (US$ Million)

Table 32 Asia-Pacific Sterile Injectables Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 33 Asia-Pacific Sterile Injectables Market Value, By Therapeutic Area, 2022-2033 (US$ Million)

Table 34 Asia-Pacific Sterile Injectables Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 35 Asia-Pacific Sterile Injectables Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 36 Asia-Pacific Sterile Injectables Market Value, By Country, 2022-2033 (US$ Million)

Table 37 South America Sterile Injectables Market Value, By Molecule, 2022-2033 (US$ Million)

Table 38 South America Sterile Injectables Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 39 South America Sterile Injectables Market Value, By Therapeutic Area, 2022-2033 (US$ Million)

Table 40 South America Sterile Injectables Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 41 South America Sterile Injectables Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 42 South America Sterile Injectables Market Value, By Country, 2022-2033 (US$ Million)

Table 43 Middle East and Africa Sterile Injectables Market Value, By Molecule, 2022-2033 (US$ Million)

Table 44 Middle East and Africa Sterile Injectables Market Value, By Drug Class, 2022-2033 (US$ Million)

Table 45 Middle East and Africa Sterile Injectables Market Value, By Therapeutic Area, 2022-2033 (US$ Million)

Table 46 Middle East and Africa Sterile Injectables Market Value, By Route of Administration, 2022-2033 (US$ Million)

Table 47 Middle East and Africa Sterile Injectables Market Value, By Distribution Channel, 2022-2033 (US$ Million)

Table 48 Middle East and Africa Sterile Injectables Market Value, By Country, 2022-2033 (US$ Million)

Table 49 Pfizer Inc.: Overview

Table 50 Pfizer Inc.: Product Portfolio

Table 51 Pfizer Inc.: Key Developments

Table 52 F. Hoffmann-La Roche Ltd: Overview

Table 53 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 54 F. Hoffmann-La Roche Ltd: Key Developments

Table 55 Novartis Pharmaceuticals Corporation: Overview

Table 56 Novartis Pharmaceuticals Corporation: Product Portfolio

Table 57 Novartis Pharmaceuticals Corporation: Key Developments

Table 58 Johnson & Johnson: Overview

Table 59 Johnson & Johnson: Product Portfolio

Table 60 Johnson & Johnson: Key Developments

Table 61 Sanofi: Overview

Table 62 Sanofi: Product Portfolio

Table 63 Sanofi: Key Developments

Table 64 AstraZeneca: Overview

Table 65 AstraZeneca: Product Portfolio

Table 66 AstraZeneca: Key Developments

Table 67 Amgen Inc., Overview

Table 68 Amgen Inc., Product Portfolio

Table 69 Amgen Inc., Key Developments

Table 70 Bristol-Myers Squibb Company: Overview

Table 71 Bristol-Myers Squibb Company: Product Portfolio

Table 72 Bristol-Myers Squibb Company: Key Developments

Table 73 GSK: Overview

Table 74 GSK: Product Portfolio

Table 75 GSK: Key Developments

Table 76 Takeda Pharmaceuticals U.S.A., Inc.: Overview

Table 77 Takeda Pharmaceuticals U.S.A., Inc.: Product Portfolio

Table 78 Takeda Pharmaceuticals U.S.A., Inc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 2 Global Sterile Injectables Market Share, By Molecule, 2024 & 2033 (%)

Figure 3 Global Sterile Injectables Market Share, By Drug Class, 2024 & 2033 (%)

Figure 4 Global Sterile Injectables Market Share, By Therapeutic Area, 2024 & 2033 (%)

Figure 5 Global Sterile Injectables Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 6 Global Sterile Injectables Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 7 Global Sterile Injectables Market Share, By Region, 2024 & 2033 (%)

Figure 8 Global Sterile Injectables Market Y-o-Y Growth, By Molecule, 2023-2033 (%)

Figure 9 Large Molecule Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 10 Small Molecule Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 11 Global Sterile Injectables Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 12 Monoclonal Antibodies Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 13 Cytokines Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 14 Insulin Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 15 Peptide Hormones Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 16 Vaccines Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 17 Immunoglobulins Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 18 Blood Factors Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 19 Peptide Antibiotics Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 20 Other Drug Class in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 21 Global Sterile Injectables Market Y-o-Y Growth, By Therapeutic Area, 2023-2033 (%)

Figure 22 Oncology Therapeutic Area in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 23 Cardiovascular Diseases Therapeutic Area in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 24 Infectious Diseases Therapeutic Area in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 25 Neurology Therapeutic Area in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 26 Autoimmune Diseases Therapeutic Area in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 27 Diabetes Therapeutic Area in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 28 Other Therapeutic Area in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 29 Global Sterile Injectables Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 30 Intravenous Route of Administration in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 31 Subcutaneous Route of Administration in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 32 Intramuscular Route of Administration in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 33 Global Sterile Injectables Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 34 Hospital Pharmacies Distribution Channel in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 35 Retail Pharmacies Distribution Channel in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 36 Online Pharmacies Distribution Channel in Global Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 37 Global Sterile Injectables Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 38 North America Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 39 North America Sterile Injectables Market Share, By Molecule, 2024 & 2033 (%)

Figure 40 North America Sterile Injectables Market Share, By Drug Class, 2024 & 2033 (%)

Figure 41 North America Sterile Injectables Market Share, By Therapeutic Area, 2024 & 2033 (%)

Figure 42 North America Sterile Injectables Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 43 North America Sterile Injectables Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 44 North America Sterile Injectables Market Share, By Country, 2024 & 2033 (%)

Figure 45 Europe Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 46 Europe Sterile Injectables Market Share, By Molecule, 2024 & 2033 (%)

Figure 47 Europe Sterile Injectables Market Share, By Drug Class, 2024 & 2033 (%)

Figure 48 Europe Sterile Injectables Market Share, By Therapeutic Area, 2024 & 2033 (%)

Figure 49 Europe Sterile Injectables Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 50 Europe Sterile Injectables Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 51 Europe Sterile Injectables Market Share, By Country, 2024 & 2033 (%)

Figure 52 Asia-Pacific Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 53 Asia-Pacific Sterile Injectables Market Share, By Molecule, 2024 & 2033 (%)

Figure 54 Asia-Pacific Sterile Injectables Market Share, By Drug Class, 2024 & 2033 (%)

Figure 55 Asia-Pacific Sterile Injectables Market Share, By Therapeutic Area, 2024 & 2033 (%)

Figure 56 Asia-Pacific Sterile Injectables Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 57 Asia-Pacific Sterile Injectables Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 58 Asia-Pacific Sterile Injectables Market Share, By Country, 2024 & 2033 (%)

Figure 59 South America Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 60 South America Sterile Injectables Market Share, By Molecule, 2024 & 2033 (%)

Figure 61 South America Sterile Injectables Market Share, By Drug Class, 2024 & 2033 (%)

Figure 62 South America Sterile Injectables Market Share, By Therapeutic Area, 2024 & 2033 (%)

Figure 63 South America Sterile Injectables Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 64 South America Sterile Injectables Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 65 South America Sterile Injectables Market Share, By Country, 2024 & 2033 (%)

Figure 66 Middle East and Africa Sterile Injectables Market Value, 2022-2033 (US$ Million)

Figure 67 Middle East and Africa Sterile Injectables Market Share, By Molecule, 2024 & 2033 (%)

Figure 68 Middle East and Africa Sterile Injectables Market Share, By Drug Class, 2024 & 2033 (%)

Figure 69 Middle East and Africa Sterile Injectables Market Share, By Therapeutic Area, 2024 & 2033 (%)

Figure 70 Middle East and Africa Sterile Injectables Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 71 Middle East and Africa Sterile Injectables Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 72 Pfizer Inc.: Financials

Figure 73 F. Hoffmann-La Roche Ltd: Financials

Figure 74 Novartis Pharmaceuticals Corporation.: Financials

Figure 75 Johnson & Johnson: Financials

Figure 76 Sanofi: Financials

Figure 77 AstraZeneca: Financials

Figure 78 Amgen Inc., Financials

Figure 79 Bristol-Myers Squibb Company: Financials

Figure 80 GSK: Financials

Figure 81 Takeda Pharmaceuticals U.S.A., Inc.: Financials

세계 무균 주사제 시장 – 2024-2031년

Global Sterile Injectable Market - 2024-2031